摘要
Dear Editor,We report a case of HBV reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin’s lymphoma patient. Hepatitis B virus (HBV) reactivation is a well-recognized complication of patients undergoing chemotherapy or immunosuppressive therapy for lymphomas. The presence of antibodies to the
Dear Editor,
We report a case of HBV reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin＇s lymphoma patient. Hepatitis B virus （HBV） reactivation is a well-recognized complication of patients undergoing chemotherapy or immunosuppressive therapy for lymphomas. The presence of antibodies to the hepatitis B surface antigen （anti-HBs） has been identified to be a factor preventing HBV reactivation in patients with occult HBV infection receiving chemotherapy. In this paper, we present a non-Hodgkin Lymphoma patient who, before immunosuppressive therapy, displayed positive anti-HBs and positive antibodies to hepatitis B core antigens （anti-HBc）, as markers of resolved HBV infection, and developed hepatitis B surface antigen （HBsAg） and high viraemia with an HBV escape mutant after rituximab- based administration.
基金
supported by the National Basic Research Priorities Program of China (2011CB106303)
National Natural Science Foundation of China(31200699)
the Fundamental Research Funds for the Central Universities (HUST: 2012QN140)
